Recurrent Urinary Tract Infection in Adults in Latvia: 2014 Observational Study

Recurrent Urinary Tract Infection in Adults in Latvia: 2014 Observational Study
复制标题

拉脱维亚成人复发性尿路感染：2014 年观察性研究

DOI：
10.4172/2161-0959.1000208
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Harijs Čerņevskis
Harijs Čerņevskis
中科院分区：
--
文献类型：
--
作者：
Vladimirs Strazdins;Harijs Čerņevskis

文献摘要

被引文献

相似文献

抗生素耐药性是一个日益严重的世界性问题。尿路感染（UTI）也不例外。因此，定期更新细菌植物群谱数据和推荐的经验性治疗的有效性至关重要，以便在必要时进行及时和适当的修订。 这项观察性研究于2014年7月至11月进行，当时拉脱维亚各地的家庭医生提交了关于其实践中复发性UTI治疗的匿名患者数据。收到匿名患者的电子数据文件，其中113人符合纳入标准，并进行了进一步分析。 拉脱维亚成人复发性UTI人群的细菌植物群谱与其他欧洲国家的数据相当一致，在66例（58.41%）培养物中鉴定出大肠埃希菌，其中55例（58.51%）为单一培养物，11例（11.70%）为联合培养物。28例（29.79%）获得无大肠埃希菌的联合培养。 对硝基呋喃衍生物（NFDs）的敏感性存在于88例（占总培养物的91.49%），大肠埃希菌对NFDs的耐药性仅在4例（占大肠埃希菌培养物的6.06%）中发现。 目前NFD复发性UTI的首选经验性治疗可能保持不变。在拉脱维亚使用的特定NFD（Furamags®）是安全，耐受性良好和有效的一线UTI治疗选择。
Antimicrobial resistance is a growing worldwide problem. Urinary tract infection (UTI) is not an exception. Therefore, it is crucial to regularly update the bacterial flora spectrum data and the efficacy of the recommended empiric treatment to make timely and appropriate amendments where necessary. This observational study was comprised in July-November 2014, when family physicians across Latvia submitted the anonymous patient data on recurrent UTI treatment in their practice. Anonymous patients’ electronic data files were received, 113 of those met the inclusion criteria and were further analyzed. Bacterial flora spectrum in Latvian adult recurrent UTI population was fairly consistent with data from other European countries, with Escherichia coli identified in 66 (58.41%) cultures, of those as monoculture in 55 (58,51%) and as combined culture in 11 (11.70%) cases. Combined cultures without Escherichia coli were obtained in 28 (29.79%) cases. Sensitivity against Nitrofuran derivatives (NFDs) was present in 88 cases (91.49% of total cultures); Escherichia coli resistance against NFDs was found in only 4 cases (6.06% of Escherichia coli cultures). The current first-choice empiric treatment of recurrent UTI by NFDs may stay unchanged. Particular NFD used in Latvia (Furamags®) is safe, well-tolerated and effective first-line UTI treatment choice.